Alexion Pharmaceuticals, Inc.
NASDAQ: ALXN
$182.50
+$0.00 (+0.0%)
Closing Price on July 28, 2021
ALXN Articles
These are the top analyst downgrades and cautious research notes from Wall Street for Monday, January 6.
Published:
ThinkstockAny time investors look for companies growing sales the most, one area that almost always stands out is the up and coming biotech stocks. After all, sales can grow from close to nothing...
Published:
ThinkstockEven though the equity strategy team at UBS has downgraded U.S. equities to Neutral from Outperform, they remain very positive on large cap biotechnology names. Acknowledging in their...
Published:
Last Updated:
ThinkstockBiotechnology stocks have had an extremely solid first half of the year. The analysts at Cowen Group point out that expectations are very high and many of the stocks have already made big...
Published:
Last Updated:
When we screen stocks at the Wall Street firms we cover, we always are anxious to provide our readers with the stocks that the top firms feel have the most upside from current trading levels to their...
Published:
Last Updated:
ThinkstockThe higher the market climbs, the harder it becomes for investors to find solid stock ideas to add or scale in to their portfolios. With the market currently teetering on what seems like an...
Published:
Last Updated:
ThinkstockBiotech has strongly outperformed the S&P 500 since January of 2011. The NASDAQ Biotechnology Index (NBI) is up 90%, and the AMEX Biotechnology index (BTK) is up 50%, versus the 28%...
Published:
Last Updated:
When we started off 2013, most of the Wall St. firms we follow put out their top stock picks for the year. We covered those various lists so our readers could get an idea which way research analysts...
Published:
Last Updated:
Thinkstock24/7 Wall St. has always wondered about the confusing universe of biotech exchange-traded funds (ETFs). Biotech stocks can rise or fall regardless of the market direction, and the sector...
Published:
Jon OggThese are some of this Wednesday’s top analyst upgrades, downgrades and initiations seen from Wall St. research calls. Access Midstream Partners L.P. (NYSE: ACMP) reiterated Outperform but...
Published:
Last Updated:
ThinkstockThe dread and fear that can come with a cancer diagnosis have their roots in its killer nature. It is the number two cause of death in Americans, second only to heart disease, according to...
Published:
Last Updated:
ThinkstockBig biotech had a stellar 2012. In 2013, though, the large biotech companies may be dwarfed in performance by the smaller players in the $1 billion to $5 billion range. If you look at the...
Published:
Last Updated:
Jon OggThe largest biotech stocks have been great performers in 2012. The question is whether that can be sustained in 2013. If Wall St. analysts are correct, biotech and biohealth investors are...
Published:
Last Updated:
ThinkstockWe have tracked the key short interest changes in the following biotech and emerging pharma companies: Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Amgen Inc. (NASDAQ: AMGN), Arena...
Published:
We have tracked the key short interest changes in the following biotech and emerging pharma companies: Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Amgen Inc. (NASDAQ: AMGN), Arena Pharmaceuticals...
Published:
Last Updated: